Myeloproliferative Neoplasms: Symptoms, Complications, and When to Suspect

Myeloproliferative neoplasms (MPNs)—polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF)—are clonal hematopoietic stem cell disorders with overlapping features.

Common Symptoms (Cytokine-Mediated)

  • Fatigue, weakness (often disproportionate to anemia)
  • Night sweats, low-grade fever
  • Weight loss, early satiety (splenomegaly)
  • Pruritus (especially aquagenic—after bathing; classic for PV)
  • Bone pain, gout (hyperuricemia)

Physical Findings

  • Splenomegaly (PV, PMF; ET less common)
  • Hepatomegaly (PMF, advanced PV)
  • Ruddy complexion (PV)
  • Erythromelalgia: burning, redness, warmth in extremities (ET, PV; platelet-mediated)

Major Complications

  • Thrombosis: Arterial (MI, stroke, TIA) and venous (DVT, PE, Budd-Chiari, portal vein). Leading cause of morbidity/mortality.
  • Hemorrhage: Acquired von Willebrand (extreme thrombocytosis), platelet dysfunction.
  • Transformation: To AML (~5–10% PMF, 2–5% PV/ET at 10 yrs) or accelerated phase MF.
  • Myelofibrosis progression: ET/PV → post-PV/ET MF.

Diagnostic Clues

  • PV: Hb >16.5 (M), >16.0 (F) g/dL; JAK2 V617F >95%; low EPO.
  • ET: Platelets >450×10⁹/L; JAK2 (50–60%), CALR (25–30%), MPL (3–5%).
  • PMF: Anemia, teardrop cells, leukoerythroblastosis, fibrosis (reticulin/collagen), JAK2/CALR/MPL.

Risk-Stratified Management

Focus on thrombosis prevention: phlebotomy (PV), aspirin (most), cytoreduction (hydroxyurea, interferon, ruxolitinib for MF) per IPSET-thrombosis, DIPSS-plus scores.

Multidisciplinary care (hematology, cardiology, genetics) improves outcomes.

Blood Disorders - Related Articles